P892 - INCREASED CARBOHYDRATE INTAKE DOES NOT ALTER INSULIN RESISTANCE IN TYPE 2 DIABETIC PATIENTS

P892

INCREASED CARBOHYDRATE INTAKE DOES NOT ALTER INSULIN RESISTANCE IN TYPE 2 DIABETIC PATIENTS

O. Sobotka^1,2,*, M. Ticha^2,3, P. Skorepa^1,2,4, J. Dusbabova¹, L. Sobotka^1,2

¹3rd Department of Internal Medicine-Metabolism and Gerontology, University Hospital Hradec Kralove, ²3rd Department of Internal Medicine-Metabolism and Gerontology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, ³Department of Internal Medicine, Pardubice Hospital, Pardubice, ⁴Department of Military Internal Medicine and Military Hygiene, University of Defence, Military Faculty of Medicine, Hradec Kralove, Czech Republic

Rationale: Carbohydrate (CHO) intake has long been considered a major contributor to insulin resistance (IR), prompting recommendations for reduced CHO in managing type 2 diabetes. However, previous findings from our group showed that increased CHO intake did not worsen IR in a small diabetic cohort. To validate these preliminary observations, this study included a larger sample to further assess the effects of elevated CHO intake on IR.

Methods: Fifteen patients with type 2 diabetes participated. During the first week, they received a standard diabetic diet with 250 g of CHO daily. In the second week, 150 g of maltodextrin was added daily, split across three meals. Plasma glucose was continuously monitored. At the end of each dietary phase, a 100 g CHO test meal was administered, and plasma glucose, insulin, and C-peptide levels were measured.

Results: Adding maltodextrin did not significantly affect glucose tolerance. The plasma glucose AUC after the CHO test meal remained nearly unchanged: 48.6 h·mmol/L (43.4–60.4) vs. 48.6 h·mmol/L (44.0–60.7). Insulin and C-peptide responses showed modest, non-significant declines: insulin AUC from 179.6 h·U/L (79.2–543.3) to 135.4 h·U/L (87.3–451.1), and C-peptide AUC from 11.0 h·nmol/L (4.6–13.0) to 9.5 h·nmol/L (6.5–12.3).

Conclusion: Our findings support earlier results that short-term increased CHO intake does not worsen IR in type 2 diabetes. These data question the routine restriction of CHO in diabetic nutrition. Given their anabolic role and energy yield, CHO may be a useful component—particularly in hospitalized or recovering patients—without adverse metabolic effects, suggesting a more balanced role in clinical nutrition.

Disclosure of Interest: None declared